Sunshine Biopharma (SBFM) Q4 2025 Annual Earnings — Miss Estimates

Screener

Reported April 3, 2026

Revenue$8.6MMiss by $1.4M

EPS-$0.30Miss by $0.03

Revenue estimate$10.0M

EPS estimate-$0.27

Next report

Nov 12, 2026 (in a month)

Revenue estimate$9.6M

EPS estimate-$0.17

Versus estimates

Revenue

Q2 2026$9.3MBeat by $563.7K Q1 2026$8.1MMiss by $1.1M

Q4 2025$8.6MMiss by $1.4M

Q3 2025$9.4MMiss by $1.7M Q2 2025$9.4MMiss by $1.7M Q1 2025$8.9M

Diluted EPS

Q2 2026-$1.15Beat by $0.05 Q1 2026-$0.25Miss by $0.09

Q4 2025-$0.30Miss by $0.03

Q3 2025-$0.19Miss by $0.06 Q2 2025-$0.39Miss by $0.28 Q1 2025-$0.44

FAQ

When did Sunshine Biopharma report Q4 2025 earnings?: Sunshine Biopharma (SBFM) reported Q4 2025 earnings on April 3, 2026.
What were Sunshine Biopharma's Q4 2025 revenue and EPS?: Sunshine Biopharma reported revenue of $8.6M and eps of $-0.30 for Q4 2025.
Did Sunshine Biopharma beat estimates in Q4 2025?: Revenue missed the consensus estimate of $10.0M by $1.4M. EPS missed the consensus estimate of $-0.27 by $0.03.
Where can I find Sunshine Biopharma's Q4 2025 SEC filings?: You can read the 10-K periodic report (0001683168-26-002644) directly on SEC EDGAR. The filing index links above go to sec.gov.

Ask the moment Sunshine Biopharma reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Harbor at dusk